Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.67 |
| ▸ | STS | P08842 | 9/20 | 0.63 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.50 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.48 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381342 | 1.00 | SHBG (0.67) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL7043160 | 0.90 | SHBG (0.64) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL2849680 | 0.85 | STS (0.47) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL712799 | 0.84 | STS (0.70) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL6869676 | 0.84 | STS (0.70) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL3908652 | 0.82 | ABCC1 (0.70) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL8629445 | 0.82 | STS (0.80) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL17515290 | 0.81 | STS (0.61) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL7096088 | 0.81 | ESR1 (0.68) | SHBGSTSABCC4ABCC1CYP2C9 | |
| SCHEMBL6633753 | 0.81 | STS (0.44) | SHBGSTSABCC4ABCC1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599493-B1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LTD (GB) | 2010-11-24 | — | — | EP | claimed |
| EP-0862577-B1 | SULPHAMATE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE DERIVATIVES, METHODS OF PRODUCING THEM AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM | JENAPHARM GMBH (DE) | 1999-04-14 | — | — | EP | claimed |
| US-8492570-B2 | 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action | STERIX LIMITED (GB) | 2013-07-23 | — | — | US | disclosed |
| US-RE42132-E1 | have special action with respect to tubulin polymerization inhibition and can be used for treating prostate cancer, breast cancer, colon cancer, non-small-cell-lung cancer, or primary dermal microvascular endothelial cell proliferation; 2-methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-yl sulfamate | STERIX LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| EP-1599493-B1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1284273-B1 | Estra-1,3,5(10)-trien-3-sulfamates a process for their production and pharmaceutical compositions containing them | STERIX LTD (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1594884-B1 | ANTITUMORAL 18A-HOMOESTRA-1,3,5(10)-TRIEN-3-YL 2-SUBSTITUTED SULFAMATES | STERIX LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-20090221841-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-7427610-B2 | 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action | STERIX LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7244762-B2 | For therapy of prostate cancer | STERIX LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20060211670-A1 | Antitumoral18a-homoestra-1,3,5(10)-trien-3yl 2-substituted sulfamates | STERIX LIMITED (GB) | 2006-09-21 | — | — | US | disclosed |
| EP-1212346-A1 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | JENAPHARM GmbH (DE) | 2002-06-12 | — | — | EP | disclosed |
| EP-1212346-A1 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | JENAPHARM GmbH (DE) | 2002-06-12 | — | — | EP | disclosed |
| EP-1212346-A1 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | JENAPHARM GmbH (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001018028-A8 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS FOR INHIBITING OESTRONE SULFATASE | JENAPHARM GMBH (DE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001018028-A8 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS FOR INHIBITING OESTRONE SULFATASE | JENAPHARM GMBH (DE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001018028-A1 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS FOR INHIBITING OESTRONE SULFATASE | JENAPHARM GMBH & CO. KG (DE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001018028-A1 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS FOR INHIBITING OESTRONE SULFATASE | JENAPHARM GMBH & CO. KG (DE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001018028-A1 | NOVEL C13-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL-SULFAMATES, A METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS FOR INHIBITING OESTRONE SULFATASE | JENAPHARM GMBH & CO. KG (DE) | 2001-03-15 | — | — | WO | disclosed |
| US-6080735-A | SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES | JENAPHARM GMBH & CO. KG (DE) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211670-A1 | Antitumoral18a-homoestra-1,3,5(10)-trien-3yl 2-substituted sulfamates | NR5A1, CYP19A1, SULT1E1 | SHBG 14/4885STS 16/4885ABCC4 1876/4885 |
| US-20090221841-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | SULT1E1, SULT1A1, SULT2A1 | SHBG 14/4885STS 5/4885ABCC4 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.